Vericel (NASDAQ:VCEL) Hits New 52-Week High at $60.15


Share on StockTwits

Vericel Co. (NASDAQ:VCEL) shares reached a new 52-week high on Thursday . The stock traded as high as $60.15 and last traded at $60.15, with a volume of 3332 shares traded. The stock had previously closed at $55.47.

Several equities analysts have recently weighed in on VCEL shares. BTIG Research lifted their target price on shares of Vericel from $45.00 to $56.00 in a research note on Monday, February 22nd. SVB Leerink boosted their price objective on shares of Vericel from $50.00 to $60.00 and gave the company an “outperform” rating in a research note on Wednesday, March 3rd. HC Wainwright boosted their price objective on shares of Vericel from $44.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, March 3rd. Oppenheimer cut shares of Vericel from an “outperform” rating to a “market perform” rating in a research note on Monday, January 11th. Finally, TheStreet raised shares of Vericel from a “c” rating to a “b-” rating in a research note on Wednesday, February 24th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $48.63.

The stock has a market capitalization of $2.66 billion, a P/E ratio of -5,771,000.00 and a beta of 3.11. The stock’s fifty day moving average price is $49.80 and its two-hundred day moving average price is $33.97.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Tuesday, February 23rd. The biotechnology company reported $0.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.05. The firm had revenue of $45.23 million during the quarter, compared to analyst estimates of $45.05 million. Vericel had a net margin of 0.12% and a return on equity of 0.13%.

In related news, CEO Dominick Colangelo sold 40,000 shares of the company’s stock in a transaction on Monday, March 29th. The shares were sold at an average price of $51.01, for a total transaction of $2,040,400.00. Following the completion of the sale, the chief executive officer now directly owns 206,540 shares in the company, valued at approximately $10,535,605.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jonathan Mark Hopper sold 17,924 shares of the company’s stock in a transaction on Tuesday, March 30th. The shares were sold at an average price of $51.40, for a total transaction of $921,293.60. Following the sale, the insider now owns 27,966 shares of the company’s stock, valued at $1,437,452.40. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Schonfeld Strategic Advisors LLC increased its position in Vericel by 66.9% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 68,626 shares of the biotechnology company’s stock valued at $1,272,000 after purchasing an additional 27,499 shares during the period. Scout Investments Inc. increased its position in Vericel by 6.7% during the 4th quarter. Scout Investments Inc. now owns 393,921 shares of the biotechnology company’s stock valued at $12,164,000 after purchasing an additional 24,657 shares during the period. Nisa Investment Advisors LLC increased its position in Vericel by 302.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,595 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,950 shares during the period. Knights of Columbus Asset Advisors LLC increased its position in Vericel by 41.4% during the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 105,442 shares of the biotechnology company’s stock valued at $3,256,000 after purchasing an additional 30,861 shares during the period. Finally, Cornerstone Investment Partners LLC purchased a new position in Vericel during the 4th quarter valued at $211,000. Institutional investors own 93.11% of the company’s stock.

Vericel Company Profile (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Read More: Hedge Funds – Risk or Reward?

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.